Therapy in myotonic disorders and in muscle channelopathies

Neurological Sciences

Volumn 21, Issue 5 SUPPL., 2000, Pages

  Meola, G ^a   Sansone, V ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Muscle channelopathies; Myotonic disorders; Therapy

Indexed keywords

ACETAZOLAMIDE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALPHA TOCOPHEROL; AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; BACLOFEN; CALCIUM CHANNEL; CARBAMAZEPINE; CARBONATE DEHYDRATASE INHIBITOR; CHLORIDE CHANNEL; DANTROLENE; DIAZOXIDE; DICLOFENAMIDE; DISOPYRAMIDE; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; IMIPRAMINE; LIDOCAINE; LOCAL ANESTHETIC AGENT; MEXILETINE; NIFEDIPINE; PHENYTOIN; PINACIDIL; POTASSIUM ION; PRASTERONE SULFATE; PROCAINAMIDE; SALBUTAMOL; SELENIUM; SODIUM CHANNEL; TESTOSTERONE ENANTATE; TOCAINIDE; TROGLITAZONE; UNINDEXED DRUG;

CLINICAL TRIAL; CONFERENCE PAPER; GENOTYPE; HUMAN; MOLECULAR GENETICS; MUSCLE WEAKNESS; MYOTONIC DYSTROPHY; PATCH CLAMP; PERIODIC PARALYSIS; PHENOTYPE; THOMSEN DISEASE;

EID: 0034444232     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100720070009     Document Type: Conference Paper

References (85)

1. Meola G (2000) Myotonic dystrophies. Curr Opin Neurol 13:519-525
2. Meola G (2000) Clinical and genetic heterogeneity in myotonic dystrophies. Muscle Nerve 23:1789-1799
3. The International Myotonic Dystrophy Consortium (IMDC) (2000) New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). Neurology 54:1218-1221
4. Ashcroft FA (2000) Ion channels and disease. Channelopathies. Academic, San Diego
5. Thomsen J (1876) Tonische Krämpfe in willkürlich beweglichen Muskeln in Folge von ererbter psychischer Disposition (ataxia muscularis). Dtsch Z Nervenheilkd 37:58-104
6. Becker PE (1957) Zur Frage der Heterogenic der erblichen Myotonien. Nervenarzt 28:455-460
7. Fontaine B, Khurana TS, Hoffman EP et al (1990) Hyperkalemic periodic paralysis and the adult muscle sodium channel alfa-subunit gene. Science 250:1000
8. Koch MC, Steinemeyer K, Lorenz C, Ricker K, Wolf F, Otto M, Zoll B, Lehmann-Horn F, Grzeschik KH, Jenisch TJ (1992) The skeletal muscle chloride channel in dominant and recessive human myotonia. Science 257:797-800
9. Lehmann-Horn F, Rudel R (1995) Hereditary non-dystrophic myotonias and periodic paralysis. Curr Opin Neurol 8:402-410
10. Lehmann-Horn F, Jurkat-Rott K (1999) Voltage-gated ion channels and hereditary disease. Physiol Rev 79(4):1317-1372
11. Ptacek LJ, George AL, Griggs RC, Tawil R, Kallen RG, Barchi RL, Robertson M, Leppert MF (1991) Identification of a mutation in the gene causing hyperkalemic periodic paralysis. Cell 67(5):1021-1027
12. Ptacek LJ, Tawil R, Griggs RC et al (1994) Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. Cell 77:1
13. Sansone V, Griggs RC, Meola G, Ptacek LJ, Barohn R, Iannaccone S, Bryan W, Baker N, Janas S, Scott W, Ririe D, Tawil R (1997) Andersen's syndrome: a distinct periodic paralysis. Ann Neurol 42(3):305-312
14. Steiner H (1909) Myopathologische Beiträge 1. Über das klinische und anatomische Bild der Muskelschwunds der Myotoniker. Dtsch Z Nervenheilkd 37:58-104
15. Backman E, Henriksson KG (1990) Effect of sodium selenite and vitamin E treatment in myotonic dystrophy. J Intern Med 228(6):577-581
16. Chyatte SB, Rudman D, Patterson JH, Ahmann P, Jordan A (1974) Human growth hormone in myopathy: myotonic dystrophy, Duchenne muscular dystrophy, and limb-girdle muscular dystrophy. South Med J 64:170-172
17. Durelli L, Mutani R, Fassio F, Satta A, Bartoli E (1982) Taurine and hyperexcitable human muscle: effect of taurine on potassium-induced hyperexcitability of dystrophic motonic and normal muscles. Ann Neurol 11:258-265
18. Fitting JW, Lauenberger (1989) Procainamide for dyspnea in myotonic dystrophy. Am Rev Respir Dis 140(5):1442-1445
19. Gascon GG, Staton RD, Patterson BD, Konewko PJ, Wilson H, Carlson KM, Brumback RA (1989) A pilot controlled study of the use of imipramine to reduce myotonia. Am J Phys Med Rehabil 68(5):215-220
20. Griggs RC, Pandya S, Florence JM, Brooke MH, Kingston W, Miller JP, Chutkow J, Herr BE, Moxley RT 3rd (1989) Randomized controlled trial of testosterone in myotonic dystrophy. Neurology 39:219-222
21. Guilleminault C, Flagg WH, Coburn SC, Dement WC (1978) Baclofen trial in six myotonic dystrophy patients. Acta Neurol Scand 57(3):232-238
22. Kashiwagi K, Nagafuchi S, Sekiguchi N, Yagamata A, Iwata I, Furuya H, Kato M, Niho Y (1999) Troglitazone not only reduced insulin resistance but also improved myotonia in a patient with myotonic dystrophy. Eur Neurol 41:171-172
23. Mamoli B, Dal-Bianco P, Zeitlhofer K (1983) Effect of dantrolene sodium in myotonic dystrophy. Eur Neurol 22(1):29-34
24. Milner-Brown HS, Miller RG (1990) Myotonic dystrophy: quantification of muscle weakness and myotonia and the effect of amitriptyline and exercise. Arch Phys Med Rehabil 71(12):983-987
25. Sugino M, Oshawa N, Ito T, Ishida S, Yamasaki H, Kimura F, Shinoda K (1998) A pilot study of dehydroepiandrosterone sulfate in myotonic dystrophy. Neurology 51(2):586-589
26. Thornton CA, Griggs RC, Welle S et al (1993) Recombinant human growth hormone (rHGH) treatment increases lean body mass in patients with myotonic dystrophy. Neurology 43:A280 (abstract)
27. Torres C, Moxley RT, Griggs RC (1983) Quantitative testing of handgrip strength, myotonia and fatigue in myotonic dystrophy. J Neurol Sci 60(1):157-168
28. Tsuji K, Furutama D, Tagami M, Oshawa N (1999) Specific binding and effects of dehydroepiandrosterone sulfate (DHEA-S) on skeletal muscle cells: possible implication for DHEA-S replacement therapy in patients with myotonic dystrophy. Life Sci 65(1):17-26
29. Vlachopapadopoulou E, Zachwieja JJ, Gertner JM et al (1995) Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy - a clinical research center study. J Clin Endocrin Metabol 80:3715-3723
30. Cannon SC (1997) From mutation to myotonia in sodium channel disorders. Neuromusc Disord 7:241-249
31. Heinemann SH, Terlau H, Stühmer W, Imoto K, Numa S (1992) Calcium channel characteristics conferred on the sodium channel by single mutations. Nature 356:441-443
32. Lehmann-Horn, Kuther G, Ricker K, Grafe P, Ballanyi K, Rudel R (1987) Adynamia episodica hereditaria with myotonia: a non-inactivating sodium current and the effect of extra-cellular pH. Muscle Nerve 10:363-374
33. Lehmann-Horn F, Rudel R, Ricker K (1987) Membrane defects in paramyotonia congenita (Eulenburg). Muscle Nerve 10:633-641
34. Steinmeyer K, Lorenz C, Pusch M, Koch M, Jentsch TJ (1994) Multimeric structure of ClC1 chloride channel revealed by mutations in dominant myotonia congenita (Thomsen). EMBO J 13:737-743
35. W, Conti F, Suzuki M, Wang Y, Noda M, Yahagi N, Kubo H, Numa S (1989) Structural parts involved in activation and inactivation of the sodium channel. Nature 339:597-603
36. Tanabe R, Takeshima H, Mikami A, Flockerzi V, Takahashi H, Kanagawa K, Kojima M, Matsuo H, Hirose T, Numa S (1987) Primary structure of the receptor for calcium channel blockers from skeletal muscle. Nature 382:313-318
37. Tempel BL, Papazian DM, Schwarz TL, Jan YN, Jan LY (1987) Sequence of a probable potassium channel component encoded at Shaker locus of Drosophila. Science 237:770-775
38. McClatchey AI, Van der Bergh P, Pericak Vance MA, Raskind W, Verellen C, McKenna Yasek D, Rao D, Haines K, Bird JL, Brown RH, Gusella JF (1992) Temperature-sensitive mutations in the III-IV cytoplasmic loop region of the skeletal muscle sodium channel gene in paramyotonia congenita. Cell 68:769-774
39. McClatchey AI, McKenna-Yasek D, Cros D, Worthen HG, Kunel RW, Desilva SM, Cornblath DR, Gusella JF, Brown RH (1992) Novel mutations in families with unusual and variable disorders of the skeletal muscle sodium channel. Nat Genet 2:148-152
40. Papazian D, Timpe LC, Jan YN, Jan LY ( 1991 ) Alteration of voltage-dependence of Shaker potassium channel by mutations in the S4 sequence. Nature 349:305-310
41. Ptacek LJ, George AL, Barchi RL, Griggs RC, Riggs JE, Robertson M, Leppert MF (1992) Mutations in an S4 segment of the adult skeletal muscle sodium channel causes paramyotonia congenita. Neuron 5:899-906
42. Ebers GC, George AL, Barchi RL et al (1991) Paramyotonia congenita and hyperkalemic periodic paralysis are linked to the adult muscle sodium channel gene. Ann Neurol 30:810
43. Hosey MM, Lazdunski M (1988) Calcium channels: molecular pharmacology, structure and regulation. J Membrane Biol 104:81-105
44. Ptacek LJ, Tawil R, Griggs RC, Storvik D, Leppert M (1992) Linkage of atypical myotonia congenita to a sodium channel locus. Neurology 42:431
45. Ptacek LJ, Ziter FA, Roberts JW, Leppert MF (1992) Evidence of genetic heterogeneity among the nondystrophic myotonias. Neurology 42(5):1046-1048
46. Ptacek LJ, Tawil R, Griggs RC, Meola G, McManis P, Barhon RJ, Mendell JR, Harris C, Spitzen R, Santiago F, Leppert MF (1994) Sodium channel mutations in acetazolamide-responsive myotonia congenita, paramyotonia congenita, and hyperkalemic periodic paralysis. Neurology 44:1500-1503
47. Rojas CV, Wang J, Schartz LS, Hoffman EP, Powell BR, Brown RH (1991) A met-to-val mutation in the skeletal muscle Na channel alpha-subunit in hyperkalemic periodic paralysis. Nature 354:387-389
48. Sansone V, Rotondo G, Ptacek LJ, Meola G (1994) Mutation in the S4 segment of the adult skeletal sodium channel gene in an Italian paramyotonia congenita (PC) family. Ital J Neurol Sci 15:473-480
49. Wagner S, Deymeer F, Kurz LL, Benz S, Schleithoff L, Lehmann-Horn F, Serdaroglu P, Ozdemir C, Rudel R (1998) The dominant chloride channel mutant G200R causing fluctuating myotonia: clinical findings, electrophysiology, and channel pathology. Muscle Nerve 21:1122-1128
50. Eulenburg A (1886) Über einer familiäre, durch 6 Generationen verfolgbare Form congenitaler Paramyotonie. Neurol Zentralbl 5:265-272
51. Davies NP, Eunson LH, Gregory RP, Mills KR, Morrison PJ, Hanna MG (2000) Clinical, electrophysiological and molecular genetics studies in a new family with paramyotonia congenita. J Neurol Neurosurg Psychiatry 68(4):504-507
52. Fahlke C, Beck CL, George ALJ (1997) A mutation in autosomal dominant myotonia congenita affects pore properties of the muscle chloride channel. Proc Natl Acad Sci USA 94:2729-2734
53. 2+ channel from rabbit skeletal muscle. Evidence for two distinct high molecular weight subunits. J Biol Chem 262:7943-7946
54. 2+ channel. Eur J Biochem 142:449-455
55. Curtis BM, Catterall WA (1984) Purification of the calcium antagonist receptor of the voltage-sensitive calcium channel from skeletal muscle transverse tubules. Biochemistry 23:2113-2118
56. Hosey MM, Barhanin J, Schmid A, Vadaele S, Ptasienski J, O'Callahan C, Cooper C, Ladzdunski M (1987) Photoaffinity labelling and phosphorylation of a 165 kilodalton peptide associated with dihydropyridine and phenylalkylamine-sensitive calcium channels. Biochem Biophys Res Commun 147:1137-1145
57. Jarrell MA, Greer M, Maren TH (1976) The effect of acidosis in hypokalemic periodic paralysis. Arch Neurol 33(11):791-793
58. Takahashi M, Seager MJ, Jones JF, Reber BFX, Catterall WA (1987) Subunit structure of dihydropyridine-sensitive calcium channels from skeletal muscle. Proc Natl Acad Sci USA 84:5478-5482
59. Links TP, Smit AJ, Molenaar WM, Zwarts MJ, Oosterhuis HJ (1994) Familial hypokalemic periodic paralysis. Clinical, diagnostic and therapeutic aspects. J Neurol Sci 122(1):33-43
60. Griggs RC, Resnick J, Engel WK (1983) Intravenous treatment of hypokalemic periodic paralysis. Arch Neurol 40(9):539-540
61. Jackson CE, Barhon RJ, Ptacek LJ (1994) Paramyotonia congenita: abnormal short exercise test and improvement after mexiletine therapy. Muscle Nerve 17(7):763-768
62. Kwiecinski H, Ryniewicz B, Ostrsycki A (1992) Treatment of myotonia with antiarrhythmic drugs. Acta Neurol Scand 86(4):371-375
63. Ricker K, Bohlen R, Rohkamm R (1983) Different effectiveness of tocainide and hydrochlorothiazide in paramyotonia congenita with hyperkalemic episodic paralysis. Neurology 33:1615-1618
64. Riggs JE, Griggs RC, Moxley RT III, Lewis ED (1981) Acute effects of acetazolamide in hyperkalemic periodic paralysis. Neurology 31(6):725-729
65. Ceccarelli M, Rossi B, Siciliano G, Calevro L, Tarantino E (1992) Clinical and electrophysiological reports in a case of early onset myotonia congenita (Thomsen's disease) successfully treated with mexiletine. Acta Paediatrica 81(5):453-455
66. Rudel R, Dengler R, Ricker A, Haass A, Emser W (1980) Improved therapy of myotonia with the lidocainc derivative tocainide. J Neurol 222:275-278
67. Vroom FW, Jarrell MA, M are n TH (1975) Acetazolamide treatment of hypokalemic periodic paralysis. Probable mechanism of action. Arch Neurol 32(6):385-392
68. Tawil R, Moxley RT III, Griggs RC (1993) Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders. Neurology 43(6):1105-1106
69. Torres CF, Griggs RC, Moxley RT, Bender AN (1981) Hypokalemic periodic paralysis exacerbated by acetazolamide. Neurology 31(11):1423-1428
70. Tawil R, McDermott MP, Brown R Jr, Shapiro BC, Ptacek LJ, McManis PG, Dalakas MC, Spectore SA, Mendell JR, Hahn AF, Griggs RC (2000) Randomized trials of dichlorphenamide in the periodic paralysis. Working Group on Periodic Paralysis. Ann Neurol 47(1):46-53
71. Davies NP, Hanna MG (1999) Neurological channelopathies: diagnosis and therapy in the new millenium. Ann Med 31(6):406-420
72. Orndhal G, Grimby G, Grimby A, Johansson G, Wilhelmsen L (1994) Functional deterioration and selenium-vitamin E treatment in myotonic dystrophy. A placebo-controlled study. J Intern Med 235(3):205-210
73. Orndahl G, Seliden U, Hallin S, Watterqvist H, Rindby A, Selin E (1986) Myotonic dystrophy treated with selenium and vitamin E. Acta Med Scand 219(4):407-414
74. Orndahl G, Rindby A, Selin E (1983) Selenium therapy of myotonic dystrophy. Acta Med Scand 213(3):237-239
75. Kwiecinski H (1980) Treatment of myotonic dystrophy with acetazolamide. J Neurol 222 (4):261-263
76. Finlay M (1982) A comparative study of disopyramide and procainamide in the treatment of myotonia in myotonic dystrophy. J Neurol Neurosurg Psychiatry 45(5):461-463
77. Sechi GP, Traccis S, Durelli L, Monaco F, Mutani R (1983) Carbamazepine versus diphenylhydantoin in the treatment of myotonia. Eur Neurol 22(2):113-118
78. Mielke U, Haass A, Sen S, Schmidt W (1985) Antimyotonic therapy with tocainide under ECG control in the myotonic dystrophy of Curschmann-Steinert. J Neurol 232(5):271-274
79. Grant R, Sutton DL, Behan PO, Ballantyne JP (1987) Nifedipine in the treatment of myotonia in myotonic dystrophy. J Neurol Neurosurg Psychiatry 50:199-206
80. Wang P, Clausen T (1976) Treatment of attacks in hyperkalemic familial periodic paralysis by inhalation of salbutamol. Lancet 1:221-223
81. Johnsen T (1977) Trial of the prophylactic effect of diazoxide in the treatment of familial periodic paralysis. Acta Neurol Scand 56(6):525-532
82. Dalakas MC, Engel WK (1983) Treatment of 'permanent' muscle weakness in familial hypokalemic periodic paralysis. Muscle Nerve 6(3):182-186
83. Links TP, Zwarts MJ, Oosterhuis HJ (1988) Improvement of muscle strength in familial hypokalemic periodic paralysis with acetazolamide. J Neurol Neurosurg Psychiatry 51(9):1142-1145
84. Ligtenberg JJ, Van Haeften TW, Van Der Kolk LE, Smit AJ, Sluiter WJ, Reitsma WD, Links TP (1996) Normal insulin release during sustained hyperglycemia in hypokalemic periodic paralysis: role of the potassium channel opener pinacidil in impaired muscle strength. Clin Sci 91(5):503-509
85. Hanna MG, Stewart J, Shapira AH, Wood NW, Morgan-Hughes JA, Murray NM (1998) Salbutamol treatment in a patient with hyperkalemic periodic paralysis due to a mutation in the skeletal sodium channel15 gene (SCN4A). J Neurol Neurosurg Psychiatry 65(2):248-250